Cutiss Company
Cutiss AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin is expected to result in a minimally scarring outcome after transplantation. denovoSkin received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
Founded Date:
2017-03-08
Employee Number:
11-50
Headquarters:
Zürich, Zurich, Switzerland, Europe
Industry:
Anti-Aging Therapeutics & Regenerative Medicine
Super Industry:
Longevity
Phone Number:
+41 43-549-21-10
Investors:
Government of France, Innosuisse, Swisspreneur Syndicate, UZH Life Sciences Fund, Z?rcher Kantonal Bank
Ipo Status:
private
City:
Zürich
Region:
Zurich
Country:
Switzerland
Founders:
Daniela Marino, Fabienne Hartmann-Fritsch